Results 121 to 130 of about 5,158 (194)

Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients. [PDF]

Eur J Nucl Med Mol Imaging
Wenzel M, Theissen L, Groener D, Kriegmair M, Graefen M, Maurer T, Salomon G, Hoeh B, Siech C, Banek S, Chun FKH, Mandel P.   +11 more
europepmc   +1 more source

Effectiveness and Safety of Radium-223 for Bone-Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study. [PDF]

Cancer Sci
Shiota M, Tatarano S, Kamba T, Kamoto T, Igawa T, Masumori N, Uemura H, Mitsunari K, Sumiyoshi T, Uemura H, Higashijima K, Tokunaga S, Eto M.   +12 more
europepmc   +1 more source

UK real-world data of radium-223 dichloride in metastatic prostate cancer. [PDF]

Nucl Med Commun
Randhawa M, Buchanan G, Stratton IM, Race G, Challapalli A, Bottomley D, Logue J, Sundar S, Robinson A, Mclaren DB, Stevenson R, O'Sullivan JM, Sweeney L, McGrane J, Jiang X, Mazhar D, Khoo V, McPhail N, Jones RJ, National Radium-223 Dichloride Audit Group.   +19 more
europepmc   +1 more source

Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases. [PDF]

Precis Oncol
Lilieholm C, Adeniyi AO, Kwon O, Zaborek J, Kerr CP, Rojas HC, Idrissou MB, Ferreira CA, Clark PA, Clark PA, Jin WJ, Grudzinski JJ, Erbe AK, Hernandez R, Bednarz B, Morris ZS, Weichert JP.   +16 more
europepmc   +1 more source

Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights. [PDF]

J Clin Oncol
Tran PT, Wang JH, Tang C, Kiess AP.
europepmc   +1 more source

Exhalation of Rn-219 by patients treated with Radium-223. [PDF]

EJNMMI Phys
Wanke C, Pinkert J, Geworski L, Szermerski B.   +3 more
europepmc   +1 more source

Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study. [PDF]

EJNMMI Rep
Souza S, Ribeiro F, Brito A, Minekawa T, Lopes F, Matedi S, Fockink R, Anjos D, Gomes G, Silva L, Camacho M, Santos A, Araújo W, Teixeira A, Martins R, Sanches A, Hanaoka N, Tavares R, Villela-Pedras F, Mourato F, Torricelli C, Alves T, Tavares M, Lima M, Moraes A, Sasse A, Almeida P, Etchebehere E.   +27 more
europepmc   +1 more source

Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment. [PDF]

Prostate Cancer Prostatic Dis
Corn PG, Yu G, Fan Y, Zhang M, Troncoso P, Surasi DS, Liu S, Ajani JA, Logothetis CJ, Wang G, Panaretakis T, Lin SH.   +11 more
europepmc   +1 more source

Fracture risk and survival outcomes of radium-223 therapy for bone metastases in mCRPC and the modulatory role of bone-protective therapy: a systematic review and meta-analysis. [PDF]

Front Oncol
Xiao M, Liu F, Duan H.
europepmc   +1 more source

Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223: a meta-analysis of real-world evidence. [PDF]

Front Oncol
Song B, Shao H, He Y, Zhu X, Qin P.
europepmc   +1 more source